Methods for treating covid-19 with sepiapterin
The invention features methods of treating a SARS-CoV-2 infection in a subject, the method comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof.
1 . A method of therapeutic treatment of a SARS-CoV-2 infection in a human subject in need thereof, the method comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof, and wherein the method comprises mitigating acute respiratory distress.
2 . The method of claim 1 , wherein the infection is a symptomatic infection.
3 . The method of claim 1 , wherein the sepiapterin, or a pharmaceutically acceptable salt thereof, is administered as soon as the subject demonstrates one or more symptoms of SARS-CoV-2 infection.
4 . The method of claim 1 , wherein the method comprises mitigating sepsis.
5 . The method of claim 1 , wherein the effective amount of sepiapterin, or pharmaceutically acceptable salt thereof, is about 10 mg/kg to about 60 mg/kg per dose.
6 . The method of claim 1 , wherein the effective amount of sepiapterin, or pharmaceutically acceptable salt thereof, is administered once daily.
7 . The method of claim 1 , wherein the effective amount of sepiapterin, or pharmaceutically acceptable salt thereof, is administered twice daily.
8 . The method of claim 7 , wherein the effective amount of sepiapterin, or pharmaceutically acceptable salt thereof, is administered in two equal doses.
9 . The method of claim 1 , wherein the effective amount of sepiapterin, or a pharmaceutically acceptable salt thereof, is administered with food.
10 . The method of claim 9 , wherein administration to the subject occurs less than 30 minutes prior to consuming food or after consuming food.
11 . The method of claim 9 , wherein the administration to the subject is substantially at the same time as food.
12 . The method of claim 1 , wherein the sepiapterin, or a pharmaceutically acceptable salt thereof, is administered as an oral powder in suspension.
13 . The method of claim 1 , wherein the sepiapterin, or a pharmaceutically acceptable salt thereof, is administered as a suspension in a flavored suspending vehicle.
14 . The method of claim 1 , wherein the sepiapterin, or a pharmaceutically acceptable salt thereof, is administered as a suspension in water or juice.
15 . The method of claim 1 , wherein the method comprises mitigating fibrotic disease resulting from acute respiratory distress.
16 . The method of claim 1 , wherein the effective amount of sepiapterin, or pharmaceutically acceptable salt thereof, is administered for at least 14 days.
17 . The method of claim 1 , wherein the effective amount of sepiapterin, or pharmaceutically acceptable salt thereof, is administered for 14-30 days.